Study guide
6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)
BCSCP Board Certified Sterile Compounding Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, USP Standards & CSP Categories
1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions
2 Chapter 2: Facilities, Engineering Controls & Cleaning
2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures
3 Chapter 3: Environmental Monitoring & Facility Certification
3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols
4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique
4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity
5 Chapter 5: Beyond-Use Dating, Storage & Container Rules
5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules
6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding
6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)
7 Chapter 7: Materials, Equipment & Compounding Workflow
7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs
8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility
8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics
9 Chapter 9: Therapeutics, Administration & Patient Monitoring
9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations
10 Chapter 10: Quality Management, Records & Personnel Competency
10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence
11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain
11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA
12 Chapter 12: Safety Management, Investigations, Recalls & Waste
12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management
6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)
Key Takeaways Explain This Topic AI
USP <800> protects personnel, patients and the environment from hazardous drugs (HDs) identified on the current NIOSH list, which since December 2024 is organized into two tables.
Sterile HDs are compounded in an externally vented C-PEC (Class II BSC or CACI) inside a C-SEC. That is either an ISO Class 7 buffer room (at least 30 ACPH) with an ISO Class 7 anteroom, or an unclassified C-SCA (at least 12 ACPH) limited to Category 1 BUDs.
CSTDs are required when administering NIOSH Table 1 antineoplastic HDs if the dosage form allows, and recommended (but not required) for compounding.
Compounding PPE is an HD-resistant gown, head and hair covers, two pairs of shoe covers, and two pairs of ASTM D6978 gloves (outer pair sterile for sterile work). Eye, face and respiratory protection are added when splash or inhalation risk exists.
HD surfaces are deactivated, decontaminated, cleaned and, in sterile areas, disinfected; the C-PEC is decontaminated at least daily when used, and under the work tray at least monthly.
Last updated: September 2026
Scope and Core Purpose of USP General Chapter <800>
While USP <797> focuses on protecting the patient from receiving contaminated CSPs, USP General Chapter <800> Hazardous Drugs—Handling in Healthcare Settings focuses primarily on protecting healthcare workers and the environment from exposure to hazardous drugs (HDs). Exposure to antineoplastic agents and other hazardous drugs is linked to secondary malignancies, spontaneous abortions, congenital malformations, genetic damage, and organ toxicities.
The NIOSH List of Hazardous Drugs
USP <800> relies on the National Institute for Occupational Safety and Health (NIOSH) to identify hazardous drugs, using six criteria: carcinogenicity, developmental toxicity, reproductive toxicity, organ toxicity at low doses, genotoxicity, and structure or toxicity similar to existing HDs. The current list is the NIOSH List of Hazardous Drugs in Healthcare Settings, 2024 , published in December 2024. It replaced the 2016 list's three groups with two tables :
Table 1 : Drugs that carry manufacturer's special handling information (MSHI) and/or meet the NIOSH definition and are classified as known or probable human carcinogens (NTP "known"; IARC Group 1 or 2A). Most antineoplastics are here, along with some non-antineoplastics; for example, azathioprine and cyclosporine moved into Table 1.
Table 2 : Other drugs that meet the NIOSH definition, including some antineoplastics and many drugs with reproductive or developmental risk.
For USP <800>, "antineoplastic" means an antineoplastic drug in NIOSH Table 1 (revision bulletin official July 1, 2020). The entity must keep its own list of HDs it handles and review that list at least every 12 months.
Assessment of Risk (AoR)
A facility may perform a documented Assessment of Risk (AoR) for dosage forms of other HDs, and for NIOSH Table 1 antineoplastic final dosage forms that need no manipulation beyond counting or repackaging. The AoR considers the type of HD, dosage form, risk of exposure, packaging and manipulation. It must list each drug and dosage form individually and be reviewed at least every 12 months. USP's FAQ says reconstituting and diluting NIOSH Table 2 drugs may be covered by an AoR. However, any HD API (including hormone concentrates) and any NIOSH Table 1 antineoplastic that needs manipulation must follow full USP <800> containment.
- Engineering Controls for Sterile HD Compounding
- 1. Containment Primary Engineering Control (C-PEC)
Sterile HDs must be compounded in a ventilated enclosure providing ISO Class 5 air with vertical downflow:
Class II Biological Safety Cabinet (BSC) : Type A2 (canopy-connected), Type B1, or Type B2 (total exhaust).
Compounding Aseptic Containment Isolator (CACI) : Negative-pressure glove box.
External Venting : Every C-PEC used for sterile HDs must be externally vented . If the C-PEC supplies some or all of the room's negative pressure, or is used for sterile compounding, it must run continuously. After a power loss, repair or move, work stops. The unit is then decontaminated, cleaned and disinfected, and the manufacturer's recovery time is allowed before compounding resumes.
2. Containment Secondary Engineering Control (C-SEC)
Negative Air Pressure : The hazardous cleanroom buffer suite must maintain continuous negative pressure between -0.010 and -0.030 inches water column relative to the adjacent ante-room.
Air Changes : Minimum of 30 Air Changes Per Hour (ACPH) from HEPA supply.
Ante-Room : Must be ISO Class 7 (not ISO 8), with at least 30 ACPH and at least +0.02 inch water column relative to adjacent unclassified areas. The hand-washing sink is in the anteroom, at least 1 meter from the entrance to the HD buffer room.
Alternative: C-SCA : An unclassified, externally vented room with fixed walls, negative pressure of 0.01 to 0.03 inch water column, and at least 12 ACPH. HD CSPs made there are limited to the SCA (Category 1) BUDs.
Closed System Drug-Transfer Devices (CSTDs)
A Closed System Drug-Transfer Device (CSTD) is a drug transfer device that mechanically prohibits the transfer of environmental contaminants into the system and the escape of hazardous drug or vapor concentrations outside the system.
Operational Mandates for CSTDs
Compounding : CSTDs are recommended but not required during HD compounding under USP <800>. They supplement the C-PEC and do not replace it.
Administration : CSTDs are required when administering NIOSH Table 1 antineoplastic HDs if the dosage form allows, for example when connecting secondary IV tubing to a patient's primary line.
Compatibility : A CSTD known to be physically or chemically incompatible with a specific HD must not be used for that HD. NIOSH has never finalized a universal CSTD performance test protocol.
Mechanisms : Physical barrier technologies (airtight elastomeric seals and interlocking double membranes) or air-cleaning filtration technologies (activated carbon and hydrophobic HEPA filters).
- Personal Protective Equipment (PPE) & Cleaning Protocols
- PPE for Sterile HD Compounding
Chemotherapy Gloves : Must be tested against ASTM D6978. Personnel must wear two pairs of chemo-rated gloves : the inner pair under the gown cuff and the outer pair (which must be sterile) pulled over the gown cuff. Gloves must be changed every 30 minutes or immediately if torn or contaminated.
Chemotherapy Gown : Disposable and shown to resist HD permeability (for example, polyethylene-coated), closing in the back, long-sleeved, with closed elastic or knit cuffs and no seams that let drug through. It is changed according to the manufacturer's permeation data, or every 2 to 3 hours if no data exist, and immediately after a spill or splash. ASTM F3267-22 is the newer standard for chemotherapy gowns.
Head, Hair and Shoe Covers : Required for sterile and nonsterile HD compounding. A second pair of shoe covers goes on before entering the C-SEC and comes off when leaving it, together with the gown, in the doffing area.
Eye, Face and Respiratory Protection : Required when there is a risk of splashes or inhalation, for example when working outside a C-PEC, unpacking a damaged shipment, or cleaning a spill. Goggles are used (safety glasses are not enough), and a face shield may be added. A surgical mask gives no respiratory protection. A fit-tested N95 protects against particles but not vapors, so a large spill calls for a full-facepiece chemical cartridge respirator or a PAPR. Routine compounding inside a properly working C-PEC does not by itself require a respirator.
Disposal : Outer gloves (and sleeve covers) are removed inside the C-PEC into a trace-waste container. Disposable HD PPE is never reused.
Four-Step Cleaning & Decontamination Sequence [1. Deactivation] ──► [2. Decontamination] ──► [3. Cleaning] ──► [4. Disinfection]
- (EPA Oxidizer / (Rinse / Inactivate (Surfactant / (Sterile 70% IPA)
- 2% Hypochlorite) Neutralizer) Detergent)
Deactivation : Oxidize or inactivate hazardous molecules (e.g., sodium hypochlorite, hydrogen peroxide, or peracetic acid).
Decontamination : Inactivate, neutralize, and physically remove chemical residue (surfactants or sodium thiosulfate neutralizers).
Cleaning : Remove organic and inorganic soils using a sterile neutral detergent.
Disinfection : Inhibit or destroy microbial bioburden using sterile 70% IPA.
- Medical Surveillance & Environmental Surface Wipe Sampling
- Environmental Surface Wipe Sampling Protocols
USP <800> recommends, but does not require , environmental wipe sampling for HD residue (USP FAQ). The suggested schedule is at baseline and at least every 6 months, or more often as needed. Common marker drugs are cyclophosphamide, ifosfamide, methotrexate, fluorouracil and platinum agents. There is no standard for acceptable surface contamination , so results are used to establish a baseline and to confirm containment.
Typical Sampling Locations :
- Interior work surface of the C-PEC (including intake grilles and work tray)
- Pass-through chambers and doors connecting the C-SEC to ante-room
- Staging and packaging surfaces directly adjacent to the C-PEC
- Floor areas immediately beneath and surrounding the C-PEC operator chair
- Outside surface of finished CSP containers and delivery transfer bins
Response to Measurable Residue : The designated person identifies, documents and contains the cause. That may mean reevaluating work practices, retraining personnel, deactivating, decontaminating and cleaning thoroughly, or improving engineering controls. Sampling is then repeated to confirm the cleanup worked.
Personnel Medical Surveillance Programs
USP <800> recommends, but does not require , a medical surveillance program as part of the workplace health and safety plan (USP FAQ). Recommended elements include:
Initial Baseline Health Assessment : Detailed reproductive history, occupational exposure questionnaire, physical examination, and baseline laboratory panels (complete blood count with differential, liver function tests, and renal function).
Ongoing Surveillance : Periodic health assessments, exposure history (which HDs, quantities and dosage forms, and hours handled per week), and prompt post-exposure evaluation after spills or skin or mucosal contact.
Exit Evaluations : Comprehensive health and exposure documentation maintained for at least 30 years post-employment per OSHA standards.